Journal
ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE
Volume 5, Issue 6, Pages 485-497Publisher
WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.1016/S1995-7645(12)60084-4
Keywords
Leishmaniasis; Drug resistance; Drug targets; Drugs
Funding
- Department of Biotechnology, New Delhi [BT/PR11177/MED/29/99/2008]
Ask authors/readers for more resources
The control of Leishmania infection relies primarily on chemotherapy till date. Resistance to pentavalent antimonials, which have been the recommended drugs to treat cutaneous and visceral leishmaniasis, is now widespread in Indian subcontinents. New drug formulations like amphotericin B, its lipid formulations, and miltefosine have shown great efficacy to treat leishmaniasis but their high cost and therapeutic complications limit their usefulness. In addition, irregular and inappropriate uses of these second line drugs in endemic regions like state of Bihar, India threaten resistance development in the parasite. In context to the limited drug options and unavailability of either preventive or prophylactic candidates, there is a pressing need to develop true antileishmanial drugs to reduce the disease burden of this debilitating endemic disease. Notwithstanding significant progress of leishmanial research during last few decades, identification and characterization of novel drugs and drug targets are far from satisfactory. This review will initially describe current drug regimens and later will provide an overview on few important biochemical and enzymatic machineries that could be utilized as putative drug targets for generation of true antileishmanial drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available